Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.

posted by Anonymous on 29 April 2015
Printer-friendly versionPrinter-friendly version
Nguyen LT, Gray E, Dean J, Carr M, Connell J, De Gascun C, Nguyen LA, O'Leary A, Bergin C, Hall W, Norris S.
Antivir Ther. 2015;20(8):865-9

10.3851/IMP2964